Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Doc Stone's Bierstube und Trading Room -- Ignore unavailable to you. Want to Upgrade?

To: M. Frank Greiffenstein who wrote (500)	1/28/1999 3:04:00 PM
From: Ron Sirch	Respond to of 638

Doc and Bierstube friends - My long term pick for 99 is Cyberonics and I offer up some DD for your info and comments. Cyberonics (CYBX) Designed, developed and now markets the NeuroCybernetic Prosthesis (NCP) System, an FDA-approved implantable device which stimulates the vagus nerve and has produced phenomenal results for epilepsy patients who could not get results from traditional drug therapy First new approach to the treatment of epilepsy in more than 100 years. The only medical device for the treatment of epilepsy approved by the FDA. FDA approved Cyberonic's NCP system on July 16, 1997. Similar approvals have been received from Canada and member countries of the European Union. Approvals for Japan and other Asian and Latin American countries are being sought. Payors such as Blue Cross Blue Shield, Medicare, two-thirds of the State Medicaid Programs, CHAMPUS, and Kaiser have issued favorable coverage decisions. The NCP treatment success stories are numerous and wonderful to read. The story of 11 year old Jacob of Webster, Texas has been profiled by Tom Brokow on NBC's Evening news. Jacob has gone from 2-30 seizures per day to virtually no seizures. (He had gone 60 days without a seizure when the Annual Report write up was prepared and he is now helping Cyberonics to spread the word about this remarkable device.) Jacob's story is but one of many heart warming stories in Cyberonic's "Profiles in Courage." Revenues and Earning per share for fiscal Q2 were released on 1-27-99. Cold statistics but a good measure of the success and acceptance of this life-enhancing device known as NCP. Revenues for quarter ending 12-31-98: $ Up 98% % from same quarter a year ago Up 24% from previous quarter (ending 9-30-98) Earnings (loss) for quarter ending 12-31-98: ($0.22) per share Compares to ($0.27) in previous quarter From the earnings report: "Last but not least, progress was made in the FDA-approved pilot studies using VNS to treat two other disorders covered by our method patents." In addition to epilepsy, the method patent covers Parkinson's Disease, tremor, depression, dementia, and migraine headaches according to the annual report. Potentially HUGE markets. Not in the current price IMO. Nor is the potential takeover value discussed on SI and aol boards. (St. Jude Medical holds over 2 million shares or 13.3 % and Rho Management Partners have built a stake of over 1 million shares as of 12-15-98). For further information, visit the company's web site at http://www. Cyberonics.com. You can also visit aol, SI and Yahoo boards. Not a lot of posts but a few quality posts of interest. Ron Sirch